Theseus Pharmaceuticals, Inc. (THRX) News
Filter THRX News Items
THRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
THRX News Highlights
- For THRX, its 30 day story count is now at 3.
- Over the past 25 days, the trend for THRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest THRX News From Around the Web
Below are the latest news stories about THESEUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate THRX as an investment opportunity.
Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value RightTheseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus" or the "Company"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ("Concentra") will acquire Theseus for a price per share of Theseus common stock ("Theseus common stock") of b |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to start the week with a breakdown of the biggest pre-market stock movers that are worth watching on Monday morning! |
Theseus (THRX) Up 57% in a Month on Strategic Restructuring PlanTheseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%. |
Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLCOn November 22, 2023, the board of directors (the Board) of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) received an unsolicited joint letter from funds and persons affiliated with Foresite Capital, LLC (collectively, Foresite) and funds and persons affiliated with OrbiMed Advisors LLC (collectively, OrbiMed), in which Foresite and OrbiMed indicated their intent to explore and evaluate a potential acquisition of all of the outstanding shares of common stock of the Compan |
Theseus Pharmaceuticals Inc (THRX) Explores Strategic Alternatives Amidst Workforce ReductionCompany Announces Significant Corporate Restructuring to Enhance Shareholder Value |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off Tuesday with a breakdown of all the biggest pre-market stock movers traders need to know about this morning! |
Theseus Pharmaceuticals Announces Process to Explore Strategic AlternativesTheseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that it is conducting a process exploring strategic alternatives to maximize shareholder value. |
Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare ConferenceTheseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced that the company will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14 at 9:45 a.m. ET. |
Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
Down -65.65% in 4 Weeks, Here's Why You Should You Buy the Dip in Theseus Pharmaceuticals, Inc. (THRX)The heavy selling pressure might have exhausted for Theseus Pharmaceuticals, Inc. (THRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |